- Conditions
- Lung Transplant
- Interventions
- Regadenoson infusion
- Drug
- Lead sponsor
- Christine Lau, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 83
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Ischemic Heart Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
- Interventions
- regadenoson
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ischemia
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- FFR Measurement with IV Adenoscan® then with Regadenoson
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
- Interventions
- Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity, Endothelial Dysfunction, Decreased Vascular Flow
- Interventions
- Adenosine, Regadenoson
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Coronary Artery Disease
- Interventions
- PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
- Diagnostic Test · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease
- Interventions
- Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT, Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
- Drug
- Lead sponsor
- Cardiovascular Imaging Technologies
- Industry
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Blood Brain Barrier Defect
- Interventions
- Regadenoson, Temozolomide, Microdialysis catheter
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coronary Artery Disease, Type 1 Diabetes Mellitus
- Interventions
- Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Drug · Procedure
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 60
- States / cities
- Mobile, Alabama • Fremont, California • Long Beach, California + 52 more
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Echo and myocardial contrast echocardiography perfusion imaging
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast, Single Photon Emission Computed Tomography, Multidetector Computed Tomography
- Drug · Radiation · Procedure
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 11
- States / cities
- Roseville, California • Torrance, California • Miami, Florida + 6 more
- Conditions
- Coronary Artery Disease, CAD
- Interventions
- regadenoson, Optimark®, Myocardial perfusion MRI
- Drug · Device
- Lead sponsor
- Daniel S. Berman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Premenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Adenosine, Magnetic Resonance Imaging, Regadenoson, Stress Management Therapy
- Biological · Procedure · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 55 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
- Interventions
- Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment
- Diagnostic Test · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more
- Conditions
- Coronary Artery Disease
- Interventions
- regadenoson
- Drug
- Lead sponsor
- Dipan Shah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronary Artery Disease, Diabetes Mellitus Type 2
- Interventions
- Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
- Drug · Procedure
- Lead sponsor
- Versiti Blood Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Milwaukee, Wisconsin
- Conditions
- Pulmonary Hypertension
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
- Interventions
- Aminophylline, Placebo
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Interventions
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Diagnostic Test · Device · Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana